Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $2.25, $0.37 better than the analyst estimate of $1.88. Revenue for the quarter came in at $209.36 million versus the consensus estimate of $190.12 million.

GUIDANCE:

Collegium Pharma sees FY2025 revenue of $775-785 million, versus the consensus of $751.6 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.